Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Debt-ridden Indian vaccine maker Panacea to exit hospitals

This article was originally published in Scrip

Executive Summary

The financially stretched Indian vaccines producer Panacea Biotec has put on the block its interest in an ambitious hospital enterprise as part of efforts to satisfy certain terms of a debt revamp plan.

You may also be interested in...



Two Cheers For Panacea, Will It Get Three?

Promising data from Phase I clinical trials of a dengue vaccine and a $24.3m award by UN agencies for its Easyfive-TT pentavalent vaccine bode well for Panacea Biotec, but are they enough to turn the company’s fortunes around?

Rescue Plan For Debt-Laden Panacea Sees Shares Soar

Distressed asset fund India Resurgence Fund, run by Bain Capital and the Ajay Piramal group, has announced a $144m bailout for financially ailing Panacea Biotec.

Panacea Expands Apotex Tie-Up, Drives Earnings Recovery

Panacea Biotec is expanding its partnership with Apotex to launch a copycat version of Eli Lilly’s Effient in the US, part of an alliance-building strategy with global players that the Indian firm hopes can help pull it out of an earnings tailspin.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC027009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel